Dr Mike Schopperle | Chief Executive Officer
CureMeta Llc

Dr Mike Schopperle, Chief Executive Officer, CureMeta Llc

Mike Schopperle received a Ph.D. in Biochemistry from Brandeis University and followed with postdoctoral studies in cancer research at Beth Israel Deaconess Medical Center, and a faculty position at Harvard Medical School to continue cancer stem cell research. In 2011 he founded CureMeta, a start-up biotech which focuses on novel diagnostics and therapeutics for aggressive and metastatic cancers.

Appearances:



EAC 2017 Day 2, Wednesday 1st November 2017 @ 12:45

Bstrongximab, a novel antibody-drug-conjugate targeting metastatic cancer

  • Embryonic antigens expressed in cancers but not normal tissues offer a new class of cancer targets for development of antibody-drug-conjugates
  • Bstrongximab is a human chimeric antibody-drug-conjugate with high affinity and specificity to a novel embryonic cancer target expressed in colon, gastric, pancreatic and esophageal cancers
  • In vitro and in vivo preclinical data show Bstrongximab to be a highly specific and potent cancer antibody-drug-conjugate
 

back to speakers